[ad_1]
The Food and Drug Administration (SFDA) explained that the drug Vitrakvi is intended for a specific segment of cancer patients, but not all.
In a statement released Friday, the news agency announced that some local and international media had recently approved the registration of Larotrectinib, a drug known as Vitrakvi, intended to treat certain cancers. Talk about the benefits of drugs, to the point of suggesting their ability to fully treat tumors.
"The drug works in an innovative way by preventing the growth of tumors caused by a rare genetic defect, which causes certain cancers, which makes it capable of serving and treating a specific group of cancer patients, not all, indicating that the drug Accreditation accelerated US Food and Drug Administration (FDA), a measure adopted by WHO for innovative drugs or may form the nucleus of a therapeutic future.
The studies were conducted on 55 patients, including 12 patients under 18 years of age with rare genetic mutation (NTRK). The response to the drug in the first nine months has been good. The number of patients taking this drug has reached 73%, but it has gradually decreased to 39% after the first year.
[ad_2]
Source link
